First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis
Conclusions
IFX was confirmed to be effective and safe in this population. Our results suggest that the first TL at week 2, in combination with clinical evaluation, is useful for predicting both short- and long-term outcomes, allowing an earlier decision between continuing IFX or switching to other options.
Source: Journal of Gastroenterology - Category: Gastroenterology Source Type: research
More News: Corticosteroid Therapy | Gastroenterology | Inflammatory Bowel Disease | Remicade | Ulcerative Colitis